The firm will pause development of lunresertib and camonsertib while focusing on development of two newer programs.

The firm will use the funding to advance ongoing clinical trials of its autologous cell therapies for solid tumors.

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

NEW YORK – Artificial intelligence tools based on natural language processing could ease the workload for clinical trial investigators by sifting through unstructured data in patient records and ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application by year end ...

The biotech wants to create one-time, potentially curative treatments for rheumatoid arthritis and other autoimmune diseases by editing the HLA gene.

The French firm will use the proceeds to advance its ALIGATER platform for delivering genetic payloads and move its preclinical assets toward the clinic.

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.

The changes will result in one company focused exclusively on cancer cell therapies and another on strategic transactions to build a pipeline of innovative medicines.

The investment will be used to help increase enrollment of follicular lymphoma patients in an ongoing Phase I study of Verismo's KIR-CAR therapy.